secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ainos, Inc. (AIMD)
CIK:        0001014763
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001654954-24-001299
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ainos submits clinical hold complete response to FDA for VELDONA Phase 2 COVID-19 trial
--------------------------------------------------------------------------------

- Submitted clinical hold complete response to FDA for Phase 2 trial of low-dose oral IFN-alpha VELDONA for mild COVID-19.
- Phase 2 multicenter randomized study expected in Taiwan in Q3 2024 if approved.
- Updated CMC and stability data show VELDONA can exceed minimum shelf life for biologicals.
- Plans additional IND applications in H2 2024 for oral warts (orphan drug) and Sjögren's syndrome.
- Low-dose oral VELDONA safety demonstrated in ~6,000 subjects across 68 clinical trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1014763/000165495424001299/0001654954-24-001299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1014763/000165495424001299/aimd_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-001299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer